Radical Hysterectomy Treatment & Management
- Author: Michael J Sundborg, MD, FACOG; Chief Editor: Warner K Huh, MD more...
Medical Therapy
For patients with stage IB lesions, equal cure rates may be obtained with surgery or radiation therapy. Radiation therapy consisting of pelvic teletherapy in combination with brachytherapy has traditionally been reserved for patients who are medically infirm and those with contraindications to surgery.
Adverse effects of radiation therapy can continue to manifest years after treatment has been completed. Adverse effects include vaginal atrophy, fibrosis, stenosis, and agglutination, which can severely affect sexual function; bladder dysfunction secondary to long-term effects, such as decreased pliability of the bladder; and acute bowel effects such as diarrhea. Over the long term, small bowel obstruction, small bowel fistula formation, rectal stricture, and rectovaginal fistula are risks.
However, recent data suggest that 54% of stage IB1 and 84% of stage IB2 will require postoperative adjuvant radiotherapy. The combination of two sequential radical therapies is notable for an increased complication rate. Additionally, the promising outcomes with an initial treatment of chemoradiation have brought into question radical surgery for stage IB2 and stage IIA. On the other hand, in patients with stage IIIB disease, chemoradiation followed by radical hysterectomy has been found to have an acceptable rate of complications and a survival outcome similar to that of chemoradiotherapy.[15]
Surgical Therapy
Surgical therapy is tailored to the patient and the extent of disease (see Staging). For patients with stage IA1 lesions, an extrafascial hysterectomy or cold-knife cone with adequate negative margins may be performed if future fertility is an issue. In these patients, the risk of having tumor in the pelvic lymph nodes is 0.5-1.5%.
For patients with stage IA2 lesions, a modified radical or Wertheim radical hysterectomy with pelvic lymphadenectomy is usually chosen because of the increased risk of extension beyond the primary lesion, which is approximately 7.3%. The modified radical hysterectomy differs from the classic type III hysterectomy, or Meigs radical hysterectomy, in that the surgeon removes approximately half of the uterosacral ligament, cardinal ligament, and uterine artery at the time of surgical resection. During the type III procedure, the uterosacral ligaments are taken at their attachment to the sacrum; the cardinal ligaments, at the pelvic sidewalls; and the uterine artery, at its origin from the internal iliac artery.
Preoperative Details
The preoperative workup includes evaluation for underlying pulmonary or cardiac disease that would be a relative contraindication to prolonged surgery. Consider having blood available during the operation in the event of exceptional blood loss, which may occur with radical surgery and pelvic lymphadenectomy. The radical hysterectomy is begun after the surgeon is certain that the patient is appropriately positioned on the operating table and that sequential compression devices are functioning properly. The procedure can take several hours to complete; therefore, these precautions must be taken to avoid injury to the patient.
Intraoperative Details
Strict attention to patient positioning helps decrease nerve injury during any prolonged surgery. At various points during the surgery, the surgeon must determine if the operation should continue.
Several types of incisions have been described. A vertical infraumbilical incision allows adequate exploration of the pelvic area and permits the superior extension in the event that extensive paraaortic dissection is necessary. In addition, less blood loss occurs through vertical midline incisions, which may be a consideration if the patient has personal or religious objections to transfusion. Most surgeons advocate a low transverse incision (eg, Maylard incision, Cherney incision), which allows adequate exposure, although these methods require separation of the rectus muscles either from the symphysis or by muscle-splitting techniques.
Before opening the peritoneum, some surgeons perform an extraperitoneal approach to the pelvic lymphadenectomy. In the event the hysterectomy is abandoned secondary to positive pelvic and/or paraaortic nodes, the peritoneum is undisturbed, thereby decreasing bowel morbidity during subsequent radiation therapy. After the bilateral pelvic lymphadenectomy is performed and all nodes are deemed negative for malignancy after frozen section analysis, the peritoneal cavity is opened.
The entire abdomen and pelvis are explored in a systematic fashion to evaluate for any palpable evidence of disease spread beyond the cervix. Locally, the peritoneal surfaces anterior and posterior to the cervix are carefully inspected and palpated. The uterus, fallopian tubes, ovaries, and upper abdomen are carefully inspected for evidence of gross disease.
The paravesical and pararectal spaces are opened, which allows better palpation of the parametrium for evidence of disease. Next, the bladder flap is taken down. Take caution in this endeavor because an adherent bladder flap may be an indication of tumor invading through the cervix and into the bladder. If this is discovered, consider termination of the procedure in order to give the patient the best chance at a cure via radiotherapy.
Next, the uterine artery is isolated from its origin at the internal iliac artery. This can be identified by finding the superior vesicle artery and tracing it to the hypogastric artery. The uterine artery is ligated. The uterine vein can also be identified and ligated to avoid bleeding during the remainder of the parametrial dissection. The parametrial margins are illustrated in the image below.
Radical hysterectomy specimen demonstrating the parametrial margins. The ureter is dissected from the parametrium. Begin by dissecting the ureters free from the medial leaf of the broad ligament; use of vessel loops around the ureters may be helpful for continuous identification for the remainder of the procedure. Additionally, this allows tension to be applied during the more difficult unroofing of the parametrial web of the ureter. As the ureter is dissected from the parametrial web, elevation of the uterine artery may be helpful. Also, the use of Clark clamps to clamp tissue superolateral to the ureter may facilitate division and ligation of such tissue. After dissecting the ureters from the tunnel of the cardinal ligament and moving the bladder a couple of centimeters below the cervix, the posterior dissection is performed.
Just inferior to the cervix, the posterior peritoneum is grasped with Allis clamps in order to open the Douglas pouch. The rectovaginal space can usually be dissected with blunt dissection directly in the same plane as the vagina (ie, toward the patient's feet). The peritoneum is freed bilaterally from the uterosacral ligaments. The uterosacral ligaments can then be divided to define the posterior-most boundary of the dissection. The use of Endo-GIA staplers has simplified this step of the procedure and may facilitate decreased blood loss.[16]
The cardinal ligaments are then clamped, divided, and ligated at the pelvic sidewall. This step can also be simplified with the Endo-GIA stapler. If the ovaries are to be removed, the infundibulopelvic ligament is clamped, ligated, and divided. In most premenopausal patients, the ovaries do not need to be removed because the risk of disease metastasis to the ovary with squamous carcinomas and adenocarcinomas is approximately 0.5% and 1.5%, respectively.
The parametria is then taken from its inferior attachments with multiple lateral-to-medial clamps until the vagina is reached. The vagina may be clamped with 90° angulated clamps or divided via sharp dissection after application of the Vicryl TA-55 stapler. These steps avoid a "rabbit ear" configuration of the vagina, which can be difficult to monitor clinically for evidence of recurrence. A 2-cm margin of vaginal cuff around the cervix is recommended, although this tissue retracts somewhat after being transected from its natural attachment to the vagina.
Radical hysterectomy specimen demonstrating the vaginal margin. Careful attention to hemostasis upon completion of the operation is essential to prevent postoperative hematoma and its associated complications. Most authors no longer close the retroperitoneal spaces, nor do they place drains in the pelvis. A suprapubic catheter or silastic transurethral catheter is placed, usually followed by continuous mass closure.
Postoperative Details
Careful detail to postoperative care is essential in order to decrease postoperative morbidity. Early ambulation, aggressive pulmonary toilet, and deep venous thrombosis prophylaxis are critical postoperative considerations. Depending on the radical nature of the procedure, the patient should retain a Foley or suprapubic catheter for several days or weeks after the procedure. Regardless, voiding trials are performed to ensure that the patient can completely empty her bladder. This helps prevent bladder distension and damage.
Follow-up
After the initial treatment, the patient is closely monitored with a thorough history, physical examinations, pelvic examinations, and Pap smears every 3 months for the first 2 years. The interval between examinations increases to every 6 months for up to 5 years. Approximately 90% of patients who are destined to have recurrences do so within the first 2 years after completion of initial therapy. History and physical examination findings direct the need for further tests. For example, a patient who reports new-onset cough or hemoptysis should have a chest radiograph taken to seek evidence of recurrence in the chest.
For excellent patient education resources, visit eMedicine's Cancer and Tumors Center. Also, see eMedicine's patient education article Cervical Cancer.
Complications
Intraoperative complications include damage to surrounding structures during the intended procedure. Injury may occur to the bladder, bowel, ureters, pelvic vessels, and nerves. Large-volume blood loss and subsequent need for transfusion may occur. As with any abdominopelvic operation for cancer, these patients are at an extremely high risk for deep venous thrombosis and subsequent embolism. Because the upper 2 cm of the vagina are removed, some patients may note vaginal shortening, particularly if even more of the vagina was removed because of stage IIA disease or in the event that postoperative adjuvant radiation therapy was administered.
Postoperative complications include wound complications such as skin separation, abscess, and dehiscence (eg, seroma, hematoma). Poor healing due to comorbid illnesses, such as obesity, steroid dependence, chronic obstructive pulmonary disease, and poor preoperative nutritional status, can significantly contribute to an increased risk of wound complications.
Postoperative issues involving the ureter, which may be significantly devitalized during the dissection, include ureteral stricture and fistula. Bladder complications, such as overflow incontinence, urinary retention, loss of bladder sensation, and detrusor instability, occur because of bilateral disruption of parasympathetic and sympathetic nerve fibers of the bladder and ureter. By the third postoperative week, most patients can adequately empty the bladder. Surgical technique that spares the pelvic autonomic nerves may significantly reduce bladder function complications, as well as anorectal complications, although the use of this technique prolongs operating times.[17, 18]
Vesicovaginal fistulae may occur in the postoperative period. If radiation therapy is not indicated, repair should be delayed to allow continuous bladder drainage for several weeks, which increases potential healing and decreases inflammation secondary to the initial procedure.
Rectal dysfunction manifested by abnormal internal sphincter relaxation, decreased rectal sensation, and increased abdominal pressure required to produce a bowel movement are rarely reported, although these conditions may be the result of disruption of autonomic sensory nerves as previously described. Small bowel obstruction resulting from postoperative adhesion formation may occur as with any exploratory laparotomy. The risk of bowel complications is markedly increased with the addition of postoperative radiation therapy in addition to radical hysterectomy.
Outcome and Prognosis
Outcomes for patients with cervical cancer are largely dependent on the stage of tumor and several identified risk factors. Patients with bulky tumors (>4 cm) are at a higher risk for both nodal metastasis and pelvic recurrence. Patients with deep stromal invasion, positive vaginal margins, or positive parametrial margins are at increased risk for recurrence. Patients with positive pelvic nodes and one of the previously mentioned risk factors are usually treated with adjuvant radiation therapy to the pelvis.
The 5-year survival rate for patients with surgically treated stage I disease without positive pelvic nodes is approximately 90%; patients with positive pelvic nodes have a 5-year survival rate of 50-60%. Patients with paraaortic nodes that contain tumor have a markedly decreased 5-year survival rate of 20-45%.
Treatment outcomes for early-stage cervical cancer using surgery or radiation therapy as the primary modality are equivalent. Whether outcomes will continue to be equivalent with the addition of chemosensitizing platinum along with radiation is unknown.
Future and Controversies
A growing literature supports the use of robotic-assisted radical hysterectomy in early-stage cervical cancer; one review found that robotic-assisted radical hysterectomy is associated with minimal blood loss, a shortened hospital stay, and few operative complications.[19]
Other treatments for cervical cancer include the use of a laparoscopic and/or vaginal approach to complete all or part of the radical hysterectomy. Published reports include surgical feasibility of the traditional radical vaginal hysterectomy (the Schauta procedure), modified laparoscopically assisted radical vaginal hysterectomy, and complete laparoscopic radical hysterectomy. Some groups in Canada and France have advocated the use of radical trachelectomy with complete laparoscopic pelvic lymphadenectomy for treatment of reproductive-aged women with early invasive lesions.[20] Because these procedures have been performed on very few patients, convincing outcome data regarding the safety and equivalency of these procedures, compared with the more traditional approaches, are not yet available.
While the treatment outcomes of radical hysterectomy and radiation therapy have been noted to be equivalent, studies have shown a decrease in the death rate from the addition of chemosensitizing cisplatin to radiation therapy in patients with stage IB2 lesions and greater.[21, 22] No outcome studies have been performed to investigate chemosensitizing radiotherapy versus radical hysterectomy. Radiotherapy may again take the dominant role in the treatment of all cervical cancers if chemosensitizing cisplatin offers a survival advantage.
O'Dowd MJ, Philipp EE. The History of Obstetrics and Gynaecology. Vol 1. New York, NY: Parthenon Publishing Group; 1994:. 543-70.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. Jul-Aug 2009;59(4):225-49. [Medline]. [Full Text].
Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. Apr 3 2001;164(7):1017-25. [Medline]. [Full Text].
Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. Dec 21 1990;63(6):1129-36. [Medline].
Jones RE, Wegrzyn RJ, Patrick DR, et al. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J Biol Chem. Aug 5 1990;265(22):12782-5. [Medline].
Hellberg D, Nilsson S, Haley NJ, et al. Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers. Am J Obstet Gynecol. Apr 1988;158(4):910-3. [Medline].
Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer. Sep 15 1986;38(3):399-44. [Medline].
Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet. Dec 10 1988;2(8624):1331-5. [Medline].
Campion MJ. Preinvasive Disease. In: Berek JS, Hacker NF. Practical Gynecologic Oncology. 4th ed. 2005:265-336.
Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res. Sep 15 1991;51(18 Suppl):5019s-5022s. [Medline].
Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol. Nov 2009;201(5):485.e1-9. [Medline].
Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. Jan 1999;17(1):41-5. [Medline].
Lai CH, Yen TC, Ng KK. Surgical and radiologic staging of cervical cancer. Curr Opin Obstet Gynecol. Feb 2010;22(1):15-20. [Medline].
Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. Jan 1999;64(1):5-10. [Medline].
Fanfani F, Fagotti A, Ferrandina G, Raspagliesi F, Ditto A, Cerrotta AM, et al. Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome. Int J Gynecol Cancer. Aug 2009;19(6):1119-24. [Medline].
Patsner B. Radical abdominal hysterectomy using the ENDO-GIA stapler: report of 150 cases and literature review. Eur J Gynaecol Oncol. 1998;19(3):215-9. [Medline].
Cibula D, Velechovska P, Sláma J, Fischerova D, Pinkavova I, Pavlista D, et al. Late morbidity following nerve-sparing radical hysterectomy. Gynecol Oncol. Nov 9 2009;[Medline].
Skret-Magierlo J, Naróg M, Kruczek A, Kluza R, Kluz T, Magon T, et al. Radical hysterectomy during the transition period from traditional to nerve-sparing technique. Gynecol Oncol. Dec 9 2009;[Medline].
Lowe MP, Chamberlain DH, Kamelle SA, Johnson PR, Tillmanns TD. A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol. May 2009;113(2):191-4. [Medline].
Roy M, Plante M. Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer. Am J Obstet Gynecol. Dec 1998;179(6 Pt 1):1491-6. [Medline].
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. Apr 15 1999;340(15):1154-61. [Medline].
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. Apr 15 1999;340(15):1144-53. [Medline].
Alvarez RD, Soong SJ, Kinney WK, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early- stage squamous carcinoma of the cervix. Gynecol Oncol. Nov 1989;35(2):130-5. [Medline].
Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6(1):7-43. [Medline].
Brewer CA, Chan J, Kurosaki T, Berman ML. Radical hysterectomy with the endoscopic stapler. Gynecol Oncol. Oct 1998;71(1):50-2. [Medline].
Creasman WT, Zaino RJ, Major FJ, et al. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol. Jan 1998;178(1 Pt 1):62-5. [Medline].
Fanning J, Kraus K. Surgical stapling technique for radical hysterectomy: survival, recurrence, and late complications. Gynecol Oncol. Nov 2000;79(2):281-3. [Medline].
Fuller AF Jr, Elliott N, Kosloff C, Lewis JL Jr. Lymph node metastases from carcinoma of the cervix, stages IB and IIA: implications for prognosis and treatment. Gynecol Oncol. Apr 1982;13(2):165-74. [Medline].
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. Jan-Feb 2001;51(1):15-36. [Medline].
Hacker NF. Cervical Cancer. In: Berek JS, Hacker NF. Practical Gynecologic Oncology 4th ed. 2005;337 - 396.
Hockel M, Konerding MA, Heussel CP. Liposuction-assisted nerve-sparing extended radical hysterectomy: oncologic rationale, surgical anatomy, and feasibility study. Am J Obstet Gynecol. May 1998;178(5):971-6. [Medline].
Janicek MF, Averette HE. Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin. Mar-Apr 2001;51(2):92-114; quiz 115-8. [Medline].
Kilgore LC, Orr JW Jr, Hatch KD, et al. Peritoneal cytology in patients with squamous cell carcinoma of the cervix. Gynecol Oncol. Sep 1984;19(1):24-9. [Medline].
Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. Aug 23 1997;350(9077):535-40. [Medline].
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. Apr 15 1999;340(15):1137-43. [Medline].
Orr JW Jr. Cervical cancer. Surg Oncol Clin N Am. Apr 1998;7(2):299-316. [Medline].
Orr JW Jr, Orr PJ, Bolen DD, Holimon JL. Radical hysterectomy: does the type of incision matter?. Am J Obstet Gynecol. Aug 1995;173(2):399-405; discussion 405-6. [Medline].
Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. Apr 2000;18(8):1606-13. [Medline].
Possover M, Stober S, Plaul K, Schneider A. Identification and preservation of the motoric innervation of the bladder in radical hysterectomy type III. Gynecol Oncol. Nov 2000;79(2):154-7. [Medline].
Randall ME, Michael H, Vermorken J. Uterine Cervix. In: Hoskins WJ, Perez CA, Young RC, et al. Principles and Practice of Gynec. 2005;743-822.
Roy M, Plante M, Renaud MC, Tetu B. Vaginal radical hysterectomy versus abdominal radical hysterectomy in the treatment of early-stage cervical cancer. Gynecol Oncol. Sep 1996;62(3):336-9. [Medline].
Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA. Oct 1 1997;278(13):1096-101. [Medline].
Shingleton HM, Orr JW. Historical aspects, pathogenesis, and epidemiology. In: Shingleton HM, Orr JW, eds. Cancer of the Cervix: A Clinical Approach. 1st ed. Philadelphia, Pa: Lippincott-Raven; 1995:. 1-15.
Shingleton HM, Orr JW. Screening. In: Cancer of the Cervix: A Clinical Approach. 1st ed. Lippincott-Raven;1995:16-33.
Spirtos NM, Schlaerth JB, Kimball RE, et al. Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy. Am J Obstet Gynecol. Jun 1996;174(6):1763-7; discussion 1767-8. [Medline].
Tarraza HM, Ellerkmann RM. Pelvic radical surgery. Surg Oncol Clin N Am. Apr 1998;7(2):399-416. [Medline].
Trimbos JB, Maas CP, Deruiter MC, et al. A nerve-sparing radical hysterectomy: guidelines and feasibility in Western patients. Int J Gynecol Cancer. May-Jun 2001;11(3):180-6. [Medline].
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. May 1999;17(5):1339-48. [Medline].
Whitney CW, Stehman FB. The abandoned radical hysterectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. Dec 2000;79(3):350-6. [Medline].

